Cancer Science & Therapy

Nawal A Al-Hamadi

Publications

• Review Article
  Valsartan Attenuates Cardiotoxicity in Breast Cancer Patients A fter Chemotherapy
  Author(s): Nawal A Al-Hamadi, Imad Al-Sabri, Amina B Aldujele, Salam J Al-Fatlawi and Zuhair AllebbanNawal A Al-Hamadi, Imad Al-Sabri, Amina B Aldujele, Salam J Al-Fatlawi and Zuhair Allebban
  
  Objective: To determine whether valsartan would be useful in attenuating Adriamycin/Cyclophosphamide/ Herceptin (ACH)-induced cardiotoxicity and to assess the role of biomarkers as indicators of cardiotoxicity in patients with breast cancer undergoing cancer therapy. Background: Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart disease. The administration of cancer drugs, in particular (ACH) is associated with increased risk of cardiotoxicity. The use of herceptin improves survival of women with early-stage positive human epidermal growth factor receptor 2 (HER2) breast cancer but also adds substantially to cost, toxicity, and inconvenience. Little is known about the potential role of valsartan in the prevention of ACH-mediated cardiotoxicity and the predictive role of biomarker.. Read More»
  DOI: 10.4172/1948-5956.1000526

  Abstract PDF